Abstract: The present invention relates to a device for distributing tablet blanks to the dies of a tablet press. The present invention moreover relates to a system consisting of the device according to the invention and a tablet press and to a method for forming tablets from tablet blanks.

Abstract: The invention relates to a dosage form comprising a physiologically effective amount of a physiologically active substance (A), a synthetic, semi-synthetic or natural polymer (C), optionally one or more physiologically acceptable auxiliary substances (B) and optionally a synthetic, semi-synthetic or natural wax (D), wherein the dosage form exhibits a resistance to crushing of at least 400 N and wherein under physiological conditions the release of the physiologically active substance (A) from the dosage form is at least partially delayed.

Abstract: The present invention relates to a method for producing a medicament dosage form which consists of at least one piece which in each case comprises at least one medicament and at least one additive, the medicament and the additive being mixed and extruded from a die as a strand and the strand being cut into pieces of precise weight. The invention additionally relates to a device.

Abstract: A solid pharmaceutical dosage form that is safeguarded against abuse, comprising at least one active substance that is susceptible to abuse and at least one emetic that is spatially separate from the at least one active substance. The active substance or substances are present in the form of at least one sub-unit (a), and the at least one emetic is present in the form of at least one sub-unit (b), and the emetic from sub-unit (b) is not activated in the body if the dosage form has been correctly administered as prescribed.

Abstract: A drinking straw with a wall having a first and a second end, wherein the drinking straw comprises a reinforced section at its first and/or second end. A method for producing a drinking straw is also provided.

Abstract: A melt-formulated, multiparticulate, oral dosage form containing clavulanic acid and/or at least one physiologically acceptable salt thereof and at least one sucrose fatty acid ester and optionally further physiologically acceptable auxiliary substances; a process for producing such a dosage form, combination dosage forms with ?-lactam antibiotics, and the pharmaceutical use thereof, e.g., for treating bacterial infections.

Abstract: The invention relates to a medicament containing the racemate of tramadol in a retarded form and the (+)-enantiomer of tramadol in a non-retarded form.

Abstract: A controlled-release oral dosage formulation of a salt-forming active ingredient, wherein the active ingredient is present as at least two different salts in a solid aggregation state, wherein the two different salts have different water solubility and release the active ingredient in-vitro at different release rates, provided that oral dosage formulations are excluded which comprise a resin carrying a sulfonate group and a resin carrying a carboxyl group and which contain an active ingredient in a form fixed to these resins.

Abstract: A multiparticulate dosage form formulated to make misuse more difficult containing least one active substance with potential for misuse (A), at least one synthetic or natural polymer (C), optionally at least one natural, semi-synthetic or synthetic wax (D), at least one disintegrant (E) and optionally one or more additional physiologically compatible excipients (B), wherein the individual particles of the dosage form display a breaking strength of at least 500 N and a release of active substance of at least 75% after 45 minutes measured according to Ph.Eur. in the paddle mixer with sinker in 600 ml of aqueous buffer solution with a pH value of 1.2 at 37° C. and 75 rpm.

Abstract: The present invention relates to a process for the production of an abuse-proofed solid dosage form containing at least one active ingredient with potential for abuse and a binder with a breaking strength of =500 N, by exposing a mixture comprising the active ingredient and the binder to ultrasound and force.

Abstract: A delayed release pharmaceutical formulation containing 1-dimethylamino-3-(3-methoxyphenyl)-2-methylpentan-3-ol or a pharmaceutically acceptable salt thereof in a matrix; said matrix containing from 1 to 80 wt. % of at least one pharmaceutically acceptable, matrix-forming, hydrophilic or hydrophobic polymer and having the following in vitro dissolution rate relative to 100 wt. % of the 1-dimethylamino-3-(3-methoxyphenyl)-2-methylpentan-3-ol contained in the formulation: 3-35 wt. % released after 0.5 hour, 5-50 wt. % released after 1 hour, 10-75 wt. % released after 2 hours, 15-82 wt. % released after 3 hours, 30-97 wt. % released after 6 hours, more than 50 wt. % released after 12 hours, more than 70 wt. % released after 18 hours, and more than 80 wt. % released after 24 hours.

Abstract: A multiparticulate, pharmaceutical dosage form containing at least one antibiotic which is sparingly wettable with aqueous media or sparingly soluble in aqueous media and a combination of carrageenan and tricalcium phosphate and optionally sucrose ester. Also, an administration system having this dosage form arranged in a drinking straw with at least one barrier device for single administration, optionally together with a conveying liquid.

Abstract: A drinking straw with a wall having a first and a second end, wherein the drinking straw comprises a reinforced section at its first and/or second end. A method for producing a drinking straw is also provided.

Abstract: Transdermal therapeutic systems for administering analgesics, preferably buprenorphine or one of its pharmaceutically acceptable salts or pro-drugs, and processes for the production of such systems.

Abstract: An abuse-resistant transdermal system which contains, in addition to one or more active ingredients with potential for abuse, at least one gel-forming agent in quantities such that it forms a gel with a minimum quantity of an aqueous liquid, and contains as further agents which complicate or prevent abuse at least one emetic, and/or at least one dye as an aversive agent.

Abstract: A kit comprising a plaster, which contains a pharmaceutical active ingredient and is designed to administer the active ingredient transdermally to a human or animal to which the plaster is applied, and an agent that is separate from the plaster and at least reduces skin irritation from the plaster.

Abstract: Pharmaceutical compositions with delayed release which contains 6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol or a pharmaceutically acceptable salt thereof in a matrix with delayed active ingredient release, wherein the matrix contains 1 to 80 wt. % of one or more hydrophilic or hydrophobic polymers as pharmaceutically acceptable matrix formers and exhibits the following in vitro release rate: 3-35 wt. % (relative to 100 wt. % of active ingredient) of 6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol released after 0.5 hours, 5-50 wt. % after 1 hour, 10-75 wt. % after 2 hours, 15-82 wt. % after 3 hours, 30-97 wt. % after 6 hours, more than 50 wt. % after 12 hours, more than 70 wt. % after 18 hours, and more than 80 wt. % after 24 hours.

Abstract: The present invention relates to a process for the production of an abuse-proofed solid dosage form containing at least one active ingredient with potential for abuse and a binder with a breaking strength of =500 N, by exposing a mixture comprising the active ingredient and the binder to ultrasound and force.

Abstract: A pharmaceutical dosage form that is safeguarded against abuse containing at least one active substance that is susceptible to abuse and at least two of the following constituents (a) through (d): (a) at least one substance that irritates the nasal and/or pharyngeal region; (b) at least one viscosity increasing agent that together with a required minimum quantity of an aqueous liquid forms a gel in an extract obtained from the dosage form, which gel can still be discerned after being introduced into an additional quantity of aqueous liquid; (c) at least one antagonist for the at least one active substance that is susceptible to abuse; and (d) at least one emetic.

Abstract: Transdermal systems with an active agent such as buprenorphine and an opioid receptor antagonist are provided. The opioid receptor antagonist may include a ?, ? or ? opioid receptor antagonist. Methods of treatment using such a system are also provided.